Increasing doses of simvastatin versus combined ezetimibe/simvastatin: Effect on circulating endothelial progenitor cells

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 18, Issue 5, 2013, Pages 447-452

  Pesaro, Antonio Eduardo P ^a,b   Serrano, Carlos V ^b   Katz, Marcelo ^a   Marti, Luciana ^a   Fernandes, Juliano L ^b   Parra, Paulo R G ^b   Campos, Alexandre H ^a  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

coronary artery disease; endothelial progenitor cells; ezetimibe; simvastatin

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; CREATINE KINASE; EZETIMIBE PLUS SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG DOSE INCREASE; ENDOTHELIAL PROGENITOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

CORONARY ARTERY DISEASE; ENDOTHELIAL PROGENITOR CELLS; EZETIMIBE; SIMVASTATIN;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ENDOTHELIAL CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; SIMVASTATIN; STEM CELLS;

EID: 84882247105     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413489771     Document Type: Article

References (25)

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 ; 366 (9493). 1267-1278
2. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 ; 359 (21). 2195-2207
3. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 ; 350 (15). 1495-1504
4. Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011 ; 58 (23). 2432-2446
5. Jones PH, Nair R, Thakker KM.. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012 ; 1 (6). e001800
6. Sager PT, Melani L, Lipka L, et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol. 2003 ; 92 (12). 1414-1418
7. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005 ; 352 (1). 20-28
8. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009 ; 360 (18). 1851-1861
9. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001 ; 108 (3). 391-397
10. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol. 2003 ; 23 (7). 1185-1189
11. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005 ; 353 (10). 999-1007
12. Schmidt-Lucke C, Rössig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005 ; 111 (22). 2981-2987
13. Pesaro AE, Serrano CV, Fernandes JL, et al. Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. Int J Cardiol. 2012 ; 158 (3). 400-404
14. Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007 ; 109 (5). 1801-1809
15. Leone AM, Rutella S, Giannico MB, et al. Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial. Int J Cardiol. 2008 ; 130 (3). 457-462
16. Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow - derived endothelial progenitor cells. J Clin Invest. 2001 ; 108 (3). 399-405
17. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001 ; 103 (24). 2885-2890
18. Pirro M, Schillaci G, Romagno PF, et al. Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function. J Cardiovasc Pharmacol Ther. 2009 ; 14 (1). 14-21
19. Hristov M, Fach C, Becker C, et al. Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment. Atherosclerosis. 2007 ; 192 (2). 413-420
20. Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002 ; 105 (25). 3017-3024
21. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005 ; 111 (18). 2356-2363
22. Westerweel PE, Visseren FL, Hajer GR, et al. Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy. Eur Heart J. 2008 ; 29 (22). 2808-2817
23. Blanco-Colio LM, Martín-Ventura JL, de Teresa E, et al. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Am Heart J. 2007 ; 153 (5). 881-888
24. de Lemos JA, Morrow DA, Blazing MA, et al. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol. 2007 ; 50 (22). 2117-2124
25. Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010 ; 376 (9753). 1658-1669